Zai Lab (ZLAB) Cash from Financing Activities (2020 - 2026)
Zai Lab's (ZLAB) quarterly Cash from Financing Activities came in at $5.6 million in Q1 2026, down 87.08% year-on-year from $43.1 million in Q1 2025, and up 1396.05% quarter-over-quarter from -$430000.0 in Q4 2025.
Zai Lab (ZLAB) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Zai Lab has disclosed Cash from Financing Activities across 7 years of filings, most recently posting $5.6 million for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $5.6 million, down 87.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.8 million (down 89.93% YoY), and the FY2025 annual result was $72.4 million, down 79.32% from the prior year.
- Cash from Financing Activities came in at $5.6 million for Q1 2026 at Zai Lab, up from -$430000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $237.8 million in Q4 2024 to a low of -$3.9 million in Q1 2023.
- The 5-year median for Cash from Financing Activities is $709000.0 (2022), against an average of $24.7 million.
- Across the five-year window, Cash from Financing Activities plunged 1606.2% in 2023 and surged 60411.96% in 2024, its largest moves.
- Zai Lab's Cash from Financing Activities stood at -$199000.0 in 2022, then soared by 297.49% to $393000.0 in 2023, then soared by 60411.96% to $237.8 million in 2024, then tumbled by 100.18% to -$430000.0 in 2025, then surged by 1396.05% to $5.6 million in 2026.
- The last three Cash from Financing Activities figures came in at $5.6 million (Q1 2026), -$430000.0 (Q4 2025), and $20.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Zai Lab | 20.15 Bn | 20.05 Bn | 61.30 Mn | 5.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.57 Mn |
| Mar 31, 2026 | 5.57 Mn |
| Dec 31, 2025 | -430,000.00 |
| Dec 31, 2025 | -430,000.00 |
| Sep 30, 2025 | 20.79 Mn |
| Sep 30, 2025 | 20.79 Mn |
| Jun 30, 2025 | 8.85 Mn |
| Jun 30, 2025 | 8.85 Mn |
| Mar 31, 2025 | 43.14 Mn |
| Mar 31, 2025 | 43.14 Mn |
| Dec 31, 2024 | 237.81 Mn |
| Dec 31, 2024 | 237.81 Mn |
| Sep 30, 2024 | 42.21 Mn |
| Sep 30, 2024 | 42.21 Mn |
| Jun 30, 2024 | 22.32 Mn |
| Jun 30, 2024 | 22.32 Mn |
| Mar 31, 2024 | 47.55 Mn |
| Mar 31, 2024 | 47.55 Mn |
| Dec 31, 2023 | 393,000.00 |
| Dec 31, 2023 | 393,000.00 |